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Available online 11 May 2013Abstract New adult stem cell sources, devoid of the technical/ethical/economical barriers of those presently available, would
favor the ongoing development of in vitro cell engineering and transplantation.
Hematopoietic transplantation opened the way to and remains the most successful cell transplantation procedure. CD34+ cells
that include hematopoietic stem cells (HSCs) and hematopoietic progenitors (HPs) are presently harvested from bone
marrow (BM), cord blood or peripheral blood (after being mobilized from BM). The panel of potential donors, the quantities
of collected cells and some other technical/medical problems still represent limiting factors to their transplantation in some
patients. Steady state peripheral blood (SSPB) contains very low frequencies of CD34+ cells. They are trapped in leukoreduction
filters (LRFs), which are discarded after the preparation of therapeutic red blood cell concentrates from individual blood
donations. We recently developed a procedure allowing the easy and rapid elution of CD34+ cells from LRFs and we showed that
they are functionally similar to those harvested from other sources.
After providing an overview of the sources, interests and limitations of therapeutic HSCs presently available, we will provide
arguments based on our and others' results suggesting that SSPB could become an attractive source of HSCs
for hematopoietic transplantation and of other cell types for various research/development procedures.
© 2013 Elsevier B.V. All rights reserved.Contents
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Transplantation of autologous or allogeneic hematopoietic
stem cells (HSCs) dramatically improved the disease free
survival of numerous patients with hematological diseases and
presently remains the only widely used cellular transplantation
procedure (Deeg and Bartenstein, 2011; Gladstone and Fuchs,
2012). Bone marrow (BM) HSCs are characterized by their
life-long capacities to either remain quiescent or proliferate
and to either self-renew or differentiate (Lerner and Harrison,
1990; Bradford et al., 1997). These tightly regulated balances
allow the life-long homeostatic production ofmature functional
blood cells, as well as the adaptation/reconstitution of
hematopoiesis after infection, hemorrhage or myeloablative
stress. During the last 40 years the continuous improvement of
our knowledge about hematopoiesis and the development of
suitable in vitro techniques for the large-scale isolation,
maintenance and expansion of HSCs have increased the
numbers and indications of hematopoietic transplantations.
They have reduced in parallel the duration of the post-
transplantation cytopenia and its related morbidity/mortality
consequences.
In 1984, the identification of the CD34 glycoprotein as a
marker of HSCs and of hematopoietic progenitors (HPs) (Civin et
al., 1984) opened the way to their isolation from BM, umbilical
cord blood (CB) and blood mobilized CD34+ cells and to the
development of transplantation with in vitro expanded cells.
However medical, economical and/or technical constraints still
limit their therapeutic use in some patients and/or countries.
The main purpose of this brief review is to discuss the potential
interest of steady state peripheral blood (SSPB) CD34+ cells
trapped in leukoreduction filters (LRFs), which are discarded
after the preparation of therapeutic red blood cell (RBC)
concentrates, as a new alternative source of HSCs for research
and hematopoietic transplantation. We will also mention and
discuss briefly some other possible uses for the CD34+ cells and
other cell types eluted from these LRFs.
Current therapeutic HSC sources:
interests and limitations
Bone marrow
About 50 years ago, successful human hematopoietic trans-
plantations confirmed that transfusion of a limited number of
HSCs and HPs collected from human BMwas able to give rise tothe rapid short-term (HPs) and long-term (HSCs) reconstitu-
tion of all hematopoietic lineages in patients (Mathe et al.,
1959; Thomas, 1999). However, obtaining BM derived HSCs for
therapy faces several technical and/or economical difficul-
ties: i) it is an invasive procedure performed under general
anesthesia, thus leading to a very low but real morbidity/
mortality risk that cannot be ignored for allogeneic healthy BM
donors (Pamphilon et al., 2009); ii) due to the very low
percentage of CD34+ cells, an important volume of BM (500 to
1500 mL) must be collected and then processed through a
multistep procedure to eliminate maturing granulocytes,
platelets and RBCs. Collecting this large volume of BM induces
a moderate but real donor RBC depletion that has also to be
considered; and iii) the socio-economical impact of a BM
donation is costly if one considers that it requires a brief
hospitalization and a limited period of restricted activity. The
appearance of non-invasive and easy alternative sources of
HSCs in numbers sufficient for adults' engraftment reduced
the transplantation of BM cells to about 20%.
Mobilized adult blood HSCs
Mobilization of HSCs and HPs from their specific BM niches to
the peripheral blood (PB) after chemotherapy was first
described in 1976 (Richman et al., 1976). It rapidly led to the
development of cell therapy procedures that used the
capacity of various chemotherapeutic agents and of some
growth factors (granulocyte colony stimulating factor [G-CSF]
mostly) to induce the BM to blood egress of numerous CD34+
cells (Siena et al., 1989), containing HSCs and primitive HPs
(To et al., 1984; Körbling et al., 1986; Sato et al., 1994). Three
major reasons explain that blood mobilized CD34+ cells are
now themajor source of therapeutic HSCs: i) the good security
and tolerance of the G-CSF conditioning processes; ii) the
rapid, complete and long term hematopoietic recovery
provided by blood mobilized HSCs; and iii) the technical
improvements of cytapheresis materials and procedures.
However, the drug/growth factor “mobilization process” has
also some side effects (bone pain, fatigue, changes in blood
cells ratios) that must be taken into consideration, especially
for healthy donors (Bosi and Bartolozzi, 2010). In addition,
mobilization is inefficient in a low percentage of “poor
mobilizers” (Benboubker et al., 2001; To et al., 2011). Despite
these limitations, transplantation of blood mobilized CD34+
cells progressively became the standard procedure for auto-
and allo-graft (To et al., 2011; Körbling and Freireich, 2011)
since it largely improved the benefit/risk ratio for both the
Figure 1 Leukoreduction filters (LRFs): a new source of
CD34+ cells for cell engineering and therapy? Discarded LRFs
are processed through a rapid (b5 h) and easy 4-step procedure
less than 24 h after blood donation. The number of CD34+ cells
per blood donation (0.4 to 1.6 × 106 cells) was calculated using
published data (Bender et al., 1991; Herbein et al., 1994). The
numbers of CD34+ cells after step 1 and step 4 were measured
by flow cytometry on our samples. LRF: leukoreduction filter,
RBCs: red blood cells, WBCs: white blood cells.
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Umbilical cord blood
CD34+ cells are present at a higher percentage and have a
better competitive repopulating capacity than those of adult
BM and of blood after mobilization (Wang et al., 1997;
Holyoake et al., 1999; Rosler et al., 2000). The interest and
the reliability of CB HSCs for allogeneic transplantation are
evidenced by the fact that more than 12,000 CB trans-
plantations were performed since 1988 (Delaney et al.,
2010). However, the low number of HSCs and HPs per CB
sample (mean: 4 × 106 CD34+ cells, range: 1.8 to 12 × 106)
restricted its use to pediatric patients below 30 kg for many
years since successful transplantation requires more than
2 × 105 CD34+ cells per kg. In adults (50 to 100 kg), who need
to receive 1 to 2 × 107 CD34+ cells for successful transplanta-
tion, the small number of HSCs obtained from one CB leads to a
delayed and insufficient myeloid and lymphoid engraftment,
which induces high hemorrhagic and infectious risks (Delaney
et al., 2010; Brunstein and Laughlin, 2010). Simultaneous
transplantation of two CB units was showed to overcome this
problem (Barker et al., 2005). Several clinical trials confirmed
that the transplantation of two CB units allows a complete
hematological reconstitution in delays comparable to those
observed with BM and blood mobilized CD34+ cells (Brunstein
et al., 2007; Oran and Shpall, 2012).
Steady state peripheral blood as a source
of HSCs?
The limitations described above and some results published
years ago (briefly mentioned below and reviewed in Körbling
and Freireich, 2011) encouraged us to explore LRFs as an
alternative new source of CD34+ cells for basic research,
development and future cell therapy/engineering. Indeed, in
the 80's, it was shown by three groups that autologous HSCs
from SSPB collected by repeated cytapheresis allowed a
complete hematological reconstitution in delays comparable
to those observed with BM (Kessinger et al., 1986; Reiffers
et al., 1986; To et al., 1984). Some years later, it was
evidenced that SSPB contains 1 to 4 × 103 CD34+ cells/mL
(Bender et al., 1991; Herbein et al., 1994) and that their
counting by flow cytometry was a reliable marker of their
engrafting capacity (Siena et al., 1991).
Functional CD34+ cells can be recovered from LRFs
In most countries, elimination of white blood cells (WBCs) and
platelets from blood donations is mandatory in order to
prevent or reduce transfusion incidents/accidents. LRFs are
now commonly used for preparing therapeutic RBC concen-
trates. A 400 to 450 mL blood donation bag contains from 0.4
to 1.6 × 106 CD34+ cells that represent a potential source of
HSCs and HPs if they can be eluted from LRFs. In 2006, we
brought the “proof of principle” that the elution of functional
CD34+ cells and colony-forming-unit-granulocyte-macrophage
(CFU-GM) was easily feasible and that their numbers were
similar with two types of LRFs, having different technicaldesigns and whatever the age of the blood donor (Ivanovic
et al., 2006). We recently developed a miniaturized, rapid
and easy 4-step procedure (Fig. 1) allowing to obtain 0.4 ±
0.05 × 105 highly enriched CD34+ cells per LRF (yield: 60 ±
5%, purity rate: 84 ± 4%) (Peytour et al., 2010). Their
functional properties (cell cycle status, growth rate and
myeloid differentiation in liquid culture, or colony-forming
ability in semi-solid culture) were rather similar to those
found by others and us for SSPB and CB CD34+ cells (Herbein
et al., 1994; Ivanovic et al., 2006; Hermitte et al., 2005).
Some differences with CB CD34+ cells were however
noticed concerning their cell cycle entry and their myeloid
differentiation kinetics that are delayed respectively by
24 h and 4 days. These results suggest that the CD34+ cells
present in SSPB are quiescent thus requiring more time to
proliferate after cytokine stimulation.
Do discarded LRFs contain HSCs?
In 1951, Brecher and Cronkite demonstrated that SSPB cells
contain long-term HSCs that are able to reconstitute normal
hematopoiesis after parabiosis between irradiated and
non-irradiated animals (Brecher and Cronkite, 1951). Later
works confirmed the presence of HSCs and HPs in human and
animal SSPB (Storb et al., 1977; McCredie et al., 1971;
Kessinger et al., 1986; Reiffers et al., 1986). While it was not
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cells do not engraft immunodeficient mice. Recently, by
using NOD/SCID mice, we confirmed the data of Hirayama
(Hirayama et al., 2003) that SSPB CD34+ cells exhibit a low
engraftment capacity and demonstrated that this capacity
is dramatically enhanced after ex vivo culture of these cells
(Brunet de la Grange et al., Stem Cell Research, 2013).
Furthermore, by using an improved animal model (NOD/SCID/
IL2r-γnull (NSG) mice), we demonstrated a clearly detectable
engraftment ability of steady state SCID repopulating cells
(SRC) inside SSPB CD34+ population (unpublished results).
These results justify to explore SSPB CD34+ cells as an
alternative and innovative approach to the widely used
hematopoietic transplantation of CD34+ cells issued from
BM, CB or from blood after their mobilization.
Interest of LRF CD34+ cells for research and therapy
This abundant and easy source of CD34+ cells is presently
unexploited. For example, the French national transfusion
institute (EFS) discards and destroys by incineration more than
3 × 106 LRFs per year. We now commonly use LRF CD34+ cells
as a source of HSCs and HPs for research and development
purposes because: i) extraction and purification of CD34+ cells
from LRFs are rapid and easy; ii) pooling cells eluted from
several LRFs allows to easily adapt the number of purified
CD34+ cells to the experimental design requirements; and iii)
pooling reduces the inter-experiment variations, observed
with individual humanmaterial, that can be a problem for HSC
and HP quantitative tests. Automation and standardization of
the process would allow to constitute homogeneous and
secured large CD34+ cell pools, then cryopreserved and
easily available in public or private cell repositories for the
scientific community. These CD34+ cell vials would be helpful
for projects requiring homogeneous and standardized cellular
material. LRF CD34+ cells could also become an interesting
alternative source for HSC transplantation since they are
permanently available in most transfusion centers. The HLA
diversity of healthy blood donors is at least equivalent to the
one of CB samples stored in biobanks. In addition, freshly
harvested cells would be easily and rapidly available from a
file of healthy volunteers without the technical, ethical and
cost constraints related to long-term cryopreservation of
human CB cells.
Facing the low amount of CD34+ cells in one
blood sample
Injection to recipients of the small quantities of CD34+ cells
harvested from one blood donation would lead to a delayed
and impaired hematopoiesis reconstitution with severe (prob-
ably lethal) infectious and hemorrhagic complications. Trans-
plantation of patients with CD34+ cells from several adult
healthy donors is quite unfeasible for immunological reasons.
So, despite its potential interest in terms of cost, ethic and
availability, SSPB cannot be used today for patients' trans-
plantation. However, it is interesting to notice that trans-
plantation of patients with 8-pooled SSPB apheresis samples
allowed a complete hematopoietic transplantation (Kessinger
et al., 1986). Apheresis of 2.5 to 6 total blood volumes
(as commonly used for harvesting blood CD34+ cells mobilizedby G-CSF injections) would provide 1 to 2 × 107 SSPB CD34+
cells from one patient in a single round, thus making this
transplantation approach feasible if coupled with an efficient
expansion procedure. If one takes into consideration the real
possibility to cryopreserve the cells issued from several filters
of the same donor over a long period (several donations per
year), the potential clinical value of these steady state PB
cells becomes obvious. We recently developed innovative
clinical grade procedures able to expand CB HSCs and HPs in
numbers sufficient to overcome this therapeutic challenge
(Ivanovic et al., 2011; Duchez et al., 2012), leading to very
short WBCs (2/3 days) and platelets (one week) cytopenias.
These excellent clinical results were obtained by culturing
purified CD34+ cells in a serum-free medium (HP01-Medium,
Macopharma, Tourcoing, France) containing antioxidants and
supplemented with a specific combination of cytokines, both
of them favoring the self-renewal/differentiation balance of
HSCs. This improved culture medium will indeed be tested for
SSPB CD34+ cells extracted from LRFs and could allow to
develop clinical scale expansion procedures devoted to make
these cells transplantable to adults.
Other biological uses of cells eluted from
LRFs (Fig. 2)
Most of the potential therapeutic uses of engineered cells and
tissues did not yet reach the bedside level due to limitations
such as: i) technical/ethical difficulties to obtain some types
of stem cells; ii) insufficient knowledge of the mechanisms
controlling their self-renewal/differentiation balance and
their homing to one specific tissue; and iii) still suboptimal in
vitro cellular reprogrammation procedures. Adult stem cells
are promising sources for regenerative medicine (Zuba-Surma
et al., 2012; Sánchez et al., 2012). Those trapped in LRFs from
healthy blood donors are thus an interesting potential
material since discarded filters are easily available in large
quantities. We suggest below some possible applications for
these cells. LRF CD34+ cells are good candidates for cell/
tissue engineering such as cardiac cell therapy. Indeed,
according to the recent procedure set-up by Losordo et al.
(2007)) and latter confirmed by a phase II study (Losordo et
al., 2011), an intramyocardial injection of a low dose of
G-CSF-mobilized autologous CD34+ cells (1 × 105 cells/kg) led
to a significant functional cardiac improvement. Autologous
SSPB CD34+ cells collected by apheresis could be thus
compatible with this application and could be easily tested.
Industrial production of RBCs could also be one important
opening for LRF CD34+ cells since the procedure developed by
the group of Douay (Douay, 2010) with CB cells will probably
reach the therapeutic level in the next few years. We recently
demonstrated that LRF CD34+ cells could also give rise to RBC
production ex vivo (Vlaski et al., 2009). Using SSPB instead of
CBwould facilitate the recruitment of numerous samples from
a large panel of donors.
Reprogrammation of CD34+ cells from LRFs towards induced
pluripotent stem cells (iPS cells) could also be proposed and
tested. Chou et al. (2011) and others cited by them succeeded
in obtaining iPS cells from adult blood CD34+ cells without viral
integration and showed that blood cells have numerous
technical, ethical and biological advantages when compared
to other cell sources. Homogeneous standardized CD34+ cell
Figure 2 Discarded leukoreduction filters: a source of various cell types for multiple biological applications? Various WBC types and
platelets trapped in LRFs are recovered by counter flow elution. The schema shows their potential uses. B/T Ly: lymphocytes B and T,
iPS: induced pluripotent stem cells, LRF: leukoreduction filter, Mono: monocytes, Plts: platelets, PMN: polymorphonuclear cells,
RBCs: red blood cells, WBCs: white blood cells.
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interest for pharmacological tests exploring the toxicity/
efficiency or the cell signaling pathways of new molecules
(Zuba-Surma et al., 2012). Predictive storage of unmodified
CD34+ cells from SSPB should also be taken into consideration.
Even if the professional risk of massive irradiation or chemical
toxicity concerns a very limited number of people, the
predictive storage of their autologous SSPB CD34+ cells could
be helpful to treat them in case of BM destruction.
Despite the fact that some articles were devoted to
lymphocytes and various WBC elution from LRFs and to their
experimental uses (Meyer et al., 2005; Dietz et al., 2006;
Néron et al., 2006), this cell source was not extensively used
by immunologists or other cell biologists. The development of
cell repositories delivering specific cell samples ready-to-use,
standardized and virally safe could still favor the “industrial”
use of LRFs.Concluding remarks
HSC transplantations represent the best opportunity of
definitive cure for patients with poor prognosis hematological
malignancies. Availability of good quality grafts, which are
HLA compatible (allogeneic transplants), devoid of malignant
cells (autologous transplants), virally safe and containing
sufficient numbers of HSCs and progenitors, remains a limitingfactor for a minority of patients. Collecting CD34+ cells by BM
aspiration or by blood apheresis after cytokine mobilization is
costly because it requires sophisticated materials/procedures
to process graft cell suspensions in cell therapy units and an
important medical presence during several days to take care
of the patient and/or donor. CB samples represent an
interesting source of HSCs for allogeneic transplantations
since they offer a large panel of HLA diversity, they are
harvested without an invasive procedure and they can be
easily cryopreserved for years. But the long-term storage of
thousands of individual vials in specialized cell repositories
(mandatory for covering the population HLA diversity) is costly
and the low number of HSCs in each CB sample still limits their
use in adults even if some recent reports show that the
simultaneous transplantation of two CB resolvedmost of these
problems. Using SSPB CD34+ cells could represent an
alternative. Indeed the large panel of healthy blood donors
(if also volunteers for entering in a file of HLA typed CD34+ cell
donors) would improve the social andmedical efficiency of the
selection of HLA matched donors. It would reduce its financial
cost by reducing the number and size of bio-banks as
compared to CB. The whole process going from LRF elution
to transplantation of expanded HSCs still has to be improved,
standardized and developed according to GMP rules. This
project is worth being realized since LRFs are a source of HSCs
technically and ethically easy to obtain that will extend the
clinical possibilities of hematopoietic transplantation. For
741Discarded leukoreduction filters: A new source of stem cellssimilar reasons, other cell types trapped in LRFs should also be
considered as alternatives to other cell sources for various
biological uses.
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